Back to Search
Start Over
Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer
- Source :
- Anticancer Research. 40:4779-4785
- Publication Year :
- 2020
- Publisher :
- Anticancer Research USA Inc., 2020.
-
Abstract
- Background/aim Irinotecan is rarely used on the metastatic breast cancer (MBC) setting. S-1 is an oral mixture of tegafur, gimeracil and oteracil. We conducted this pilot study to assess efficacy and safty of chemotherapy with combined irinotecan and S-1 (IRIS). Patients and methods Irinotecan was given intravenously at 80 mg/m2 on days 1 and 8 and S-1 was given orally at 80-120 mg/day depending on body surface area for 2 weeks, repeating the cycle every 3 weeks. Results Twenty-two patients were enrolled in the study. Median age was 50.5 years (range=26-72). Nineteen patients were evaluable for response. Median overall survival and progression-free survival were 672 days (95% CI=420-967) and 166 days (95% CI=76-814), respectively. Conclusion The IRIS regimen has an acceptable safety profile and modest efficacy against MBC in patients previously heavily treated with chemotherapy. This regimen has potential to treat MBC.
- Subjects :
- Adult
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Breast Neoplasms
Pilot Projects
Irinotecan
Tegafur
Gastroenterology
Disease-Free Survival
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
In patient
Aged
Body surface area
Chemotherapy
business.industry
General Medicine
Middle Aged
medicine.disease
Metastatic breast cancer
Progression-Free Survival
Drug Combinations
Oxonic Acid
Regimen
Safety profile
Oncology
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 17917530 and 02507005
- Volume :
- 40
- Database :
- OpenAIRE
- Journal :
- Anticancer Research
- Accession number :
- edsair.doi.dedup.....a61fd55f99c3843ca47027ec2b72f1bc